Amicus Therapeutics is growing steadily with Galafold and a promising Pompe therapy, targeting $1B revenue by 2028. See why ...

GNI Group ( ($JP:2160) ) has shared an announcement. GNI Group’s subsidiary, Gyre Therapeutics, has initiated a Phase 1 clinical trial in China ...

Consequently, RNAi therapeutics as a drug class have the potential to exert a transformational effect on modern medicine. In RNAi, the target mRNA is enzymatically cleaved, leading to decreased ...

Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), currently trading at $0.58 with a market capitalization of $33.37 million, disclosed the results of its annual meeting of stockholders held on May 28, ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peripheral Nerve Injuries pipeline constitutes 10+ key companies continuously working towards ...

PYC Therapeutics Ltd’s latest earnings call for the second quarter of 2025 highlighted the company’s strategic focus on pipeline development and potential asset monetization. Despite no specific ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...